Related references
Note: Only part of the references are listed.Psoriasis: Which therapy for which patient Psoriasis comorbidities and preferred systemic agents
Shivani B. Kaushik et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Psoriasis: Which therapy for which patient Focus on special populations and chronic infections
Shivani B. Kaushik et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Commentary: Does biologic treatment of psoriasis lower the risk of cardiovascular events and mortality? A critical question that we are only just beginning to answer
Joel M. Gelfand
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Risk of Cardiovascular Morbidity in Patients With Psoriatic Arthritis: A Meta-Analysis of Observational Studies
Ari Polachek et al.
ARTHRITIS CARE & RESEARCH (2017)
COMPARISON OF RATES OF ACTIVE TUBERCULOSIS INFECTION IN THE PHASE 2 AND 3 CLINICAL TRIAL PROGRAMS FOR ANTI-IL12/23 AND ANTI-TNFS
Edward V. Loftus et al.
GASTROENTEROLOGY (2017)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
B. G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic
Eric Sorenson et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2015)
Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
Richard B. Warren et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial
Arthur Kavanaugh et al.
ARTHRITIS CARE & RESEARCH (2015)
Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris
R. Gniadecki et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
Christopher Ritchlin et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study
A. B. Kimball et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2013)
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
Iain B. McInnes et al.
LANCET (2013)
Psoriasis and risk of nonfatal cardiovascular disease in US women: a cohort study
W. -Q. Li et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Reversible Posterior Leukoencephalopathy Syndrome in a Patient Treated With Ustekinumab Case Report and Review of the Literature
David Gratton et al.
ARCHIVES OF DERMATOLOGY (2011)
Discovery and mechanism of ustekinumab A human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders
Jacqueline M. Benson et al.
MABS (2011)
Cardiovascular Disease and Risk Factors in Patients with Psoriasis and Psoriatic Arthritis
Anne-Marie Tobin et al.
JOURNAL OF RHEUMATOLOGY (2010)
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Christopher E. M. Griffiths et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial
Alice Gottlieb et al.
LANCET (2009)
A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease
William J. Sandborn et al.
GASTROENTEROLOGY (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi et al.
LANCET (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim A. Papp et al.
LANCET (2008)
Swords into plowshares: IL-23 repurposes tumor immune surveillance
John L. Langowski et al.
TRENDS IN IMMUNOLOGY (2007)
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis
Gerald G. Krueger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)